Man Group plc Has $954,000 Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Man Group plc increased its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 191.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,302 shares of the company's stock after buying an additional 28,457 shares during the period. Man Group plc's holdings in Teva Pharmaceutical Industries were worth $954,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC increased its holdings in shares of Teva Pharmaceutical Industries by 30.7% during the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after buying an additional 19,242,468 shares in the last quarter. Duquesne Family Office LLC grew its stake in shares of Teva Pharmaceutical Industries by 530.1% in the fourth quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock worth $198,303,000 after purchasing an additional 7,569,450 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its position in Teva Pharmaceutical Industries by 12.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after acquiring an additional 4,418,961 shares during the last quarter. Todd Asset Management LLC bought a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at $58,243,000. Finally, Marshall Wace LLP boosted its position in Teva Pharmaceutical Industries by 87.8% during the fourth quarter. Marshall Wace LLP now owns 5,155,402 shares of the company's stock valued at $113,625,000 after acquiring an additional 2,410,420 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Down 3.9%

Shares of NYSE TEVA traded down $0.71 during trading on Thursday, hitting $17.45. 4,659,190 shares of the company traded hands, compared to its average volume of 10,010,614. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The firm has a market capitalization of $19.78 billion, a price-to-earnings ratio of -12.04, a P/E/G ratio of 1.44 and a beta of 0.62. The business's fifty day moving average is $15.47 and its 200 day moving average is $17.36.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. During the same quarter in the prior year, the business posted $0.48 EPS. The firm's revenue was up 1.9% compared to the same quarter last year. Equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on TEVA shares. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday. They set a "buy" rating and a $25.00 price target on the stock. Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Finally, Barclays dropped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $24.50.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.